Abstract
Arovin (ancrod) treatment is generally recognized to lower fibrinogen levels and is sometimes used to decrease plasma and whole blood viscosity. The fall in fibrinogen is accompanied by a rise in fibrinogen degradation products (FDP), but none of the other clotting factors is affected. This study shows that patients undergoing surgery with subsequent Arvin treatment decrease their red cell filterability (RCF), and that this drop cannot be explained by either the surgical intervention, a direct effect of Arvin on the red cells, or the lowered fibrinogen levels. However the decrease of RCF does correlate with the rise in FDP.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Scandinavian Journal of Clinical and Laboratory Investigation
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
